Lexaria risks Nasdaq delisting after missing $1 minimum bid price rule
Reuters2026/08/10 21:07- Lexaria Bioscience received a Nasdaq notice on Aug. 4, 2026, citing failure to regain compliance with the $1 minimum bid rule.
- Nasdaq warned the stock faces delisting, subject to an appeal hearing that would stay any suspension.
- A reverse stock split took effect Aug. 3, 2026; shares are trading above $1 under new CUSIP 52886N604.
- A hearing request was filed with the required fee to keep the listing in place while the company seeks to regain compliance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Dollar: Range-bound support as Fed priced – ING
GBP/JPY Price Forecast: Six-month lows at the 209.20 area under pressure
Temple Bar Investment Trust Sept. 4 estimated NAV with debt at par value at 413.32 pence/share
The yield on the 10-year US Treasury is approaching the 5.5% red line! Societe Generale warns: Stock valuation support is failing, US stocks may face a severe shock.
Société Générale pointed out that this year’s global profit expectations have been significantly raised. Even with rising yields, this has prevented equity risk premiums from plunging.
Crypto prices
More
